CGEM - Cullinan Oncology LLC

Hold Momentum: Bearish

Recent News

Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday? - Cullinan Therapeutics ( NASDAQ:CGEM )

Benzinga • 1 year, 4 months ago • score: 0.20

A recent academic case study, published on April 22, examined using Amgen Inc's AMGN Blincyto, a bispecific CD3xCD19 T-cell engager, to treat a patient with severe systemic sclerosis. The findings have implications for Cullinan Therapeutics Inc's CGEM CLN-978, a similar CD19xCD3 bispecific T-cell ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-10 (Snapshot)

Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company is headquartered in Cambridge, Massachusetts.

52W High

$18.62

52W Low

$6.61

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

-0.07

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

6.30

EV/EBITDA (<8 favorable)

-1.46

EV/Revenue (<3 favorable)

11.55

P/S (TTM) (<3 favorable)

26.88

P/B (<3 favorable)

0.84

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

4.54%

Institutions (25–75% balanced)

107.58%

Shares Outstanding

59,074,000

Float

36,054,900

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

18,943,000

EPS (TTM)

-3.16

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.36%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-0.1690

-0.1204

Trend

Falling

Signal Cross

No cross

As of

Sep. 05, 2025